AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 526846: Xylitol, 1,5-anhydro-, triacetate

Chemical compound data from PubChem database. IUPAC Name: (4,5-diacetyloxyoxan-3-yl) acetate. Molecular Formula: C11H16O7. Molecular Weight: 260.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Provider Network Data: 2022 Quarter 2

This Provider Network Data contains information on individual and institutional providers participating in health plan networks from April through June 2022. Plan network data is collected from Medicaid, Commercial, and Exchange plans on a quarterly basis by the Department of Health, including managed care plans, as well as PPO/EPO plans.

For more information, please visit: <a href=https://pndslookup.health.ny.gov>https://pndslookup.health.ny.gov</a>
Exertional dyspnea as initial manifestation of Takayasu's arteritis – A case report and literature review

Background
          Takayasu's arteritis is a chronic systemic inflammatory disease that usually affects the aorta, its primary branches and occasionally the pulmonary and coronary arteries. Female gender in reproductive age and Asian origin are known factors associated with higher disease prevalence. The clinical manifestations vary considerably and are typically caused by limb or organ ischemia illness and fever. The estimated incidence rate in the western world is 2.6 cases per million persons per year. Occasionally, exertional dyspnea can be the sole primary clinical manifestation of Takayasu's arteritis.
        
        
          Case presentation
          We report the case of a 57-year-old woman who was referred to our institution with increasing exertional dyspnea caused by pulmonary artery involvement in Takayasu's arteritis. In a review of the literature we discuss demographic data, clinical and radiographic findings and available therapeutic options.
        
        
          Conclusions
          Dyspnea due to pulmonary artery involvement can be the initial symptom of Takayasu's arteritis. Simple clinical tests, including a complete pulse-status and blood pressure measuring at both arms can lead to the right diagnosis and should always be done beyond the auscultation of the heart and lungs in patients with dyspnea.
Incidence and Characteristics of Total Stroke in the United States

Background and Purpose
          Stroke, increasingly referred to as a "brain attack", is one of the leading causes of death and the leading cause of adult disability in the United States. It has recently been estimated that there were three quarters of a million strokes in the United States in 1995. The aim of this study was to replicate the 1995 estimate and examine if there was an increase from 1995 to 1996 by using a large administrative claims database representative of all 1996 US inpatient discharges.
        
        
          Methods
          We used the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project, release 5, which contains ≈ 20 percent of all 1996 US inpatient discharges. We identified stroke patients by using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes from 430 to 438, and we compared the 1996 database with that of 1995.
        
        
          Results
          There were 712,000 occurrences of stroke with hospitalization (95% CI 688,000 to 737,000) and an estimated 71,000 occurrences of stroke without hospitalization. This totaled 783,000 occurrences of stroke in 1996, compared to 750,000 in 1995. The overall rate for occurrence of total stroke (first-ever and recurrent) was 269 per 100,000 population (age- and sex-adjusted to 1996 US population).
        
        
          Conclusions
          We estimate that there were 783,000 first-ever or recurrent strokes in the United States during 1996,
compared to the figure of 750,000 in 1995. This study replicates and confirms the previous annual estimates of 
approximately three quarters of a million total strokes. This slight increase is likely due to the aging of the population and
the population gain in the US from 1995 to 1996.
Compound 529016: 1,4-Diethyl-2,5-dimethylbenzene

Chemical compound data from PubChem database. IUPAC Name: 1,4-diethyl-2,5-dimethylbenzene. Molecular Formula: C12H18. Molecular Weight: 162.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526662: Cyclohexen-4-methanol, acetate

Chemical compound data from PubChem database. IUPAC Name: cyclohex-3-en-1-ylmethyl acetate. Molecular Formula: C9H14O2. Molecular Weight: 154.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530639: m-Toluic acid, 3-methylbut-2-enyl ester

Chemical compound data from PubChem database. IUPAC Name: 3-methylbut-2-enyl 3-methylbenzoate. Molecular Formula: C13H16O2. Molecular Weight: 204.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer

Background
          Drug resistance in breast cancer is a major obstacle to successful chemotherapy. In this study we used cDNA microarray technology to examine gene expression profiles obtained from fine needle aspiration (FNA) of primary breast tumors before and after systemic chemotherapy. Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and to identify those expression profiles that correlate with treatment response.
        
        
          Methods
          Repeat presurgical FNA samples were taken from six patients who were to undergo primary surgical treatment. Additionally, a group of 10 patients who were to receive neoadjuvant chemotherapy underwent two FNAs before chemotherapy (adriamycin 60 mg/m2 and cyclophosphamide 600 mg/m2) followed by another FNA on day 21 after the first cycle. Total RNA was amplified with T7 Eberwine's procedure and labeled cDNA was hybridized onto a 7600-feature glass cDNA microarray.
        
        
          Results
          We identified candidate gene expression profiles that might distinguish tumors with complete response to chemotherapy from tumors that do not respond, and found that the number of genes that change after one cycle of chemotherapy was 10 times greater in the responding group than in the non-responding group.
        
        
          Conclusion
          This study supports the suitability of FNA-derived cDNA microarray expression profiling of breast cancers as a comprehensive genomic approach for studying the mechanisms of drug resistance. Our findings also demonstrate the potential of monitoring post-chemotherapy changes in expression profiles as a measure of pharmacodynamic effect and suggests that these approaches might yield useful results when validated by larger studies.
Patent AT-E401390-T1: [Translated] CYTOKINE (ZCYTOR17 LIGAND)

There is provided an antibody or antibody fragment which specifically binds to a portion of SEQ ID NO:2, wherein said portion consists of between 30 and 100 contiguous amino acids of SEQ ID NO:2, and wherein said portion contains amino acids selected from the group consisting of: (a) amino acid residues 54 to 59 of SEQ ID NO: 2; (b) amino acid residues 129 to 134 of SEQ ID NO: 2; (c) amino acid residues 53 to 58 of SEQ ID NO: 2; (d) amino acid residues 35 to 40 of SEQ ID NO: 2; (e) amino acid residues 33 to 38 of SEQ ID NO: 2; (f) amino acid residues 114 to 119 of SEQ ID NO: 2; (g) amino acid residues 101 to 105 of SEQ ID NO: 2; (h) amino acid residues 126 to 131 of SEQ ID NO: 2; (i) amino acid residues 113 to 118 of SEQ ID NO: 2; and (j) amino acid residues 158 to 162 of SEQ ID NO:2.
Compound 527330: Tiaprofenic Acid Methyl Ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2-(5-benzoylthiophen-2-yl)propanoate. Molecular Formula: C15H14O3S. Molecular Weight: 274.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Behavioral Health Barometer: West Virginia, 2014

This is a behavioral health report for the state of West Virginia. It uses the  National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.
Patent AT-E401089-T1: [Translated] ORAL PREPARATIONS CONTAINING ANTIMICROBIAL ACTIVE INGREDIENTS FOR THE PREVENTION OF SYSTEMIC DISEASES

The present invention relates to promoting whole body health in humans and animals by using topical oral compositions comprising a safe and effective amount of an antimicrobial agent in admixture with a pharmaceutically acceptable carrier, said compositions being effective in controlling bacterial-mediated diseases and conditions present in the oral cavity and in inhibiting the spread into the bloodstream of pathogenic oral bacteria, associated bacterial toxins and endotoxins, and resultant inflammatory cytokines and mediators. The present invention also encompasses methods of use of these compositions by topically applying to the oral cavity, a safe and effective amount of an antimicrobial agent to promote and/or enhance whole body health in humans and other animals.
Compound 526097: Tetradecanoic acid, 6-methyl, trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 6-methyltetradecanoate. Molecular Formula: C18H38O2Si. Molecular Weight: 314.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400556-T1: [Translated] N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYLPYRIDINE DERIVATIVES

Chemical patent from PubChem database. Patent Number: AT-E400556-T1. Title: Combinatorial Chemistry Method. Filing Date: 2001-11-07. Inventors: Kim, Young-Soo, Taylor, Elizabeth. Abstract: A combinatorial chemistry method for generating libraries of chemical compounds is disclosed, enabling rapid identification of lead compounds for drug... IPC Classifications: C07D, C07F, A61K. This patent covers 37 claims related to 2 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
NNDSS - Table II. Spotted Fever Rickettsiosis to Syphilis

NNDSS - Table II. Spotted Fever Rickettsiosis to Syphilis - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. 

Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable    Cum: Cumulative year-to-date counts.    Med: Median.    Max: Maximum. 

* Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. 

��� Illnesses with similar clinical presentation that result from Spotted fever group rickettsia infections are reported as Spotted fever rickettsiosis. Rocky Mountain spotted fever (RMSF) caused by Rickettsia rickettsii, is the most common and well-known spotted fever.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.
Network PUF - PY2021

The Network PUF (Ntwrk-PUF) is one of the seven files that make up the Marketplace PUF. The Ntwrk-PUF contains issuer-level data identifying provider network URLs. These data either originate from the Network ID template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).
Compound 525590: N,N-Dimethyl-N'-(4-chlorophenyl)-benzamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(4-chlorophenyl)-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C15H15ClN2. Molecular Weight: 258.74. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Serum organochlorines and urinary porphyrin pattern in a population highly exposed to hexachlorobenzene

Background
          Porphyria cutanea tarda (PCT) is caused by hexachlorobenzene (HCB) in several species of laboratory mammals, but the human evidence is contradictory. In a study among adults of a population highly exposed to HCB (Flix, Catalonia, Spain), the prevalence of PCT was not increased. We aimed at analysing the association of individual urinary porphyrins with the serum concentrations of HCB and other organochlorine compounds in this highly exposed population.
        
        
          Methods
          A cross-sectional study on total porphyrins was carried out in 1994 on 604 inhabitants of the general population of Flix, older than 14 years. Of them, 241 subjects (comprising a random sample and the subgroup with the highest exposure) were included for the present study. The porphyrin profile was determined by high-pressure liquid chromatography. Serum concentrations of HCB, as well as common organochlorine compounds, were determined by gas chromatography coupled to electron capture detection.
        
        
          Results
          Coproporphyrin I (CPI) and coproporphyrin III (CPIII) were the major porphyrins excreted, while uroporphyrins I and III were only detected in 2% and 36% of the subjects respectively, and heptaporphyrins I and III in 1% and 6%, respectively. CPI and CPIII decreased with increasing HCB concentrations (p < 0.05). This negative association was not explained by age, alcohol, smoking, or other organochlorine compounds. No association was found between uroporphyrin I and III excretion, nor heptaporphyrin excretion, and HCB. CPIII increased with smoking (p < 0.05).
        
        
          Conclusion
          HCB exposure in this highly exposed population did not increase urinary concentrations of individual porphyrins.
Experience collecting interim data on mortality: an example from the RALES study

Introduction
          The Randomized Aldactone Evaluation Study (RALES) randomized 822 patients to receive 25 mg spironolactone daily and 841 to receive placebo. The primary endpoint was death from all causes. Randomization began on March 24, 1995; recruitment was completed on December 31, 1996; follow-up was scheduled to continue through December 31, 1999. Evidence of a sizeable benefit on mortality emerged early in the RALES. The RALES data safety monitoring board (DSMB), which met semiannually throughout the trial, used a prespecified statistical guideline to recommend stopping for efficacy. At the DSMB's request, its meetings were preceded by an 'endpoint sweep', that is, a census of all participants to confirm their vital status.
        
        
          Methods
          We used computer simulation to evaluate the effect of the sweeps.
        
        
          Results
          The sweeps led to an estimated 5 to 8% increase in the number of reported deaths at the fourth and fifth interim analyses. The data crossed the statistical boundary at the fifth interim analysis. If investigators had reported all deaths within the protocol-required 24-h window, the DSMB might have recommended stopping after the fourth interim analysis.
        
        
          Discussion
          Although endpoint sweeps can cause practical problems at the clinical centers, sweeps are very useful if the intervals between patient visits or contact are long or if endpoints require adjudication by committee, reading center, or central laboratory.
        
        
          Conclusion
          We recommend that trials with interim analyses institute active reporting of the primary endpoints and endpoint sweeps.
Compound 525711: p-Methylbenzylidene-(3-bromophenyl)-amine

Chemical compound data from PubChem database. IUPAC Name: N-(3-bromophenyl)-1-(4-methylphenyl)methanimine. Molecular Formula: C14H12BrN. Molecular Weight: 274.15. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2015 Edition Market Readiness for Hospitals and Clinicians Data

This dataset provides the proportion of developers, by market share, that have certified 2015 edition health IT modules. Market share approximations are determined through an analysis of the certified health IT products reported by participants in the Medicare EHR Incentive Program from 2011 to 2016. Approximations use the most recently reported data for each unique clinician and hospital participant. It is important to understand how to interpret these approximations. Some clinicians and hospitals report certified software from more than one unique developer. The market share percentages in this dataset, therefore, include some double counting (the percentages will, if summed together, add up above 100 percent.) The approximations convey the percent of hospitals and clinicians who use a developer's technology, and are not to be interpreted in aggregate as the percent of all hospitals and clinicians who have access to 2015 edition certified technology.
Compound 526591: 2,2'-Bis(trimethylsilyloxy)diphenylmethane

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[2-[(2-trimethylsilyloxyphenyl)methyl]phenoxy]silane. Molecular Formula: C19H28O2Si2. Molecular Weight: 344.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401198-T1: [Translated] SLOTTED SUBSTRATE AND ASSOCIATED PRODUCTION METHOD

Techniques for fabricating an inkjet printhead include providing a printhead substrate (100), fabricating a thinfilm structure (101) on the substrate, forming a break trench (124) in a surface region of the substrate in which a feed slot is to be formed, and subsequently abrasively machining the substrate through the break trench to form the feed slot (126). The break trench can be formed by an etch process, prior to applying a barrier layer (112) to the thinfilm structure in a preferred embodiment. <IMAGE>
Compound 527850: 2,4-Dichlorobenzyl pentyl ether

Chemical compound data from PubChem database. IUPAC Name: 2,4-dichloro-1-(pentoxymethyl)benzene. Molecular Formula: C12H16Cl2O. Molecular Weight: 247.16. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Incomplete gastric metaplasia in children with insulin-dependent diabetes mellitus and celiac disease. An ultrastructural study

Background
          The association of insulin-dependent diabetes mellitus (IDDM) and celiac disease (CD) has been widely reported in children but the relationship between the two conditions is incompletely understood. Moreover, specific studies on intestinal biopsies of patients with the association of the two diseases are still lacking.
        
        
          Methods
          We studied the ultrastructure of the duodenal mucosa in 12 patients with both IDDM and CD.
        
        
          Results
          All patients had either total or partial atrophy of duodenal mucosa. In seven subjects, an accumulation of electrondense granules in the apical cytoplasm of groups of enterocytes was found. In four of them, a double population of granules existed (mean diameter: 400-800 nm and 100-200 nm respectively) showing a biphasic pattern. In the other three patients, only smaller granules (100- 200 nm) were found in the enterocytes.
        
        
          Conclusions
          The present work suggests that patients with IDDM/CD may represent a subgroup in the context of the CD population. Intestinal biopsies of such individuals often show accumulation of electrondense granules in the apical cytoplasm of enterocytes that can be interpreted as incomplete gastric metaplasia.
NNDSS - Table II. Hepatitis (viral, acute)

NNDSS - Table II. Hepatitis (viral, acute) - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable    Cum: Cumulative year-to-date counts.    Med: Median.    Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.